BioNTech SE BNTX
NASDAQ BNTX
$116.57 +5.68 (+5.12%)
At close: Aug 21, 2026 · 4:00 PM EDT

BioNTech SE (BNTX) Long-Term Debt Repayments (2019 - 2025)

BioNTech SE (BNTX) posted Long-Term Debt Repayments of -$10.0 million for Q4 2025, down 613.59% sequentially from -$1.4 million in Q3 2025.

BioNTech SE (BNTX) Long-Term Debt Repayments (2019 - 2025) Analysis & Trends

BioNTech SE has reported Long-Term Debt Repayments for 7 years, with the latest figure at -$10.0 million in Q4 2025.

  • Quarterly Long-Term Debt Repayments changed N/A year-over-year to -$10.0 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$20.3 million (up 99.29% YoY) and the FY2025 annual result came in at -$20.3 million, down 727.44% from the prior year.
  • Long-Term Debt Repayments declined to -$10.0 million in Q4 2025 per BNTX's latest filing, from -$1.4 million in the prior quarter.
  • Over five years, Long-Term Debt Repayments peaked at $1.8 billion in Q4 2023 and troughed at -$2.9 billion in Q1 2024.
  • A 5-year average of -$194.5 million and a median of -$2.5 million in 2024 frame the typical range for Long-Term Debt Repayments.
  • The sharpest annual moves came in 2022 and 2025: Long-Term Debt Repayments sank 2498912357.2% in 2022, then surged 99.83% in 2025.
  • Over 5 years, Long-Term Debt Repayments stood at -$58.0 in 2021, then plunged by 32682274.62% to -$19.0 million in 2022, then jumped by 9772.67% to $1.8 billion in 2023, then slumped by 100.14% to -$2.5 million in 2024, then slumped by 304.18% to -$10.0 million in 2025.
  • According to Business Quant data, Long-Term Debt Repayments over the past three periods registered -$10.0 million, -$1.4 million, and -$4.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Long-Term Debt Repayments (Qtr)
1 Vertex Pharmaceuticals 139.13 Bn 131.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.77 Bn 77.77 Bn 3.93 Bn -
3 Argenx Se 64.64 Bn 59.46 Bn 1.37 Bn -
4 Moderna 58.29 Bn 53.16 Bn 52.00 Mn -
5 BeOne Medicines 41.92 Bn 36.82 Bn 1.53 Bn 17.05 Mn
6 Alnylam Pharmaceuticals 31.58 Bn 28.28 Bn 992.69 Mn -
7 BioNTech SE 28.12 Bn 9.73 Bn 668.28 Mn -10.01 Mn
8 Insmed 27.39 Bn 26.22 Bn 358.27 Mn -
9 Royalty Pharma 27.27 Bn 26.43 Bn - -
10 Roivant Sciences 26.20 Bn 26.20 Bn 1.16 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 -10.01 Mn
Dec 31, 2025 -10.01 Mn
Sep 30, 2025 -1.40 Mn
Sep 30, 2025 -1.40 Mn
Jun 30, 2025 -4.19 Mn
Jun 30, 2025 -4.19 Mn
Mar 31, 2025 -4.73 Mn
Mar 31, 2025 -4.73 Mn
Jun 30, 2024 -2.48 Mn
Jun 30, 2024 -2.48 Mn
Mar 31, 2024 -2.86 Bn
Mar 31, 2024 -2.86 Bn
Dec 31, 2023 1.83 Bn
Dec 31, 2023 1.83 Bn
Sep 30, 2023 -108,859.05
Sep 30, 2023 -108,859.05
Mar 31, 2023 -1.83 Bn
Mar 31, 2023 -1.83 Bn
Sep 30, 2022 -18.96 Mn
Sep 30, 2022 -18.96 Mn